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1. Introduction 
Today advances in the design of modern drugs rely on an understanding of their 
mechanism of action. Positron Emission Tomography (PET) has proven to be an important 
imaging tool for diagnosis in oncology, cardiology and neurology and more recently in 
personalised medicine (Roach, M. et al., 2011; Smith, S.V., 2005). Its exquisite sensitivity 
(<10-9 M) has made it a valuable tool in the screening and risk assessment of new agents in 
drug development programs (Cropley, V.L. et al., 2006; Gomes, C.M.F. et al., 2011; Gregoire, 
V. et al., 2007; Lancelot, S. & Zimmer, L., 2010; Langer, A.2010; Lonsdale, M.N. & Beyer, T., 
2010; Roach, M. et al., 2011; Seam, P. et al., 2007; Truong, M.T. et al., 2011; Vyas, N.S. et al., 
2011; Wahl, R.L. et al., 2009). It has been mainly focused on the use of the classical short 
lived PET isotopes, 11C and 18F, in the evaluation of small molecular weight molecules. PET 
contributions to the molecular imaging and drug development fields however would be 
significantly enhanced if longer lived PET radioisotopes were readily available. Generally 
metal PET radioisotopes are better suited for labelling larger molecular agents such as 
peptides, proteins and particles. This chapter will review a range of metal PET radioisotopes 
under development, assess their physical characteristics and suitability for PET imaging.  
1.1 How does PET work? 
The high sensitivity of PET is related to its mode of detection. The positron (+) which is 
emitted from the PET isotope must lose sufficient energy (to <100 eV) so it is able to attach 
to an electron and form the neutral, unstable positronium. The positronium annihilates 
rapidly (within less than 150 picoseconds (ps)) to give off two 511 keV gammas 
simultaneously, in opposite directions. If the two coincident gammas are detected by the 
circumferentially arranged detectors within a fixed time period, it is assumed that they arise 
from the same radioactive source (see Figure 1). This co-registration of the gamma signals 
allows one to determine the location and concentration of the PET probe in the body 
(Lonsdale, M.N. &Beyer, 2010 T.; Smith, S.V., 2005). 
2. PET Imaging 
The quality of information gained by PET imaging is governed by the spatial resolution and 
sensitivity of PET to the radioisotope used. While the sensitivity and flexibility of PET is 
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superior to other existing imaging modalities it lacks the anatomical or structural detail 
achieved with CT and MRI (Smith, S.V., 2007). Today PET technology has evolved 
significantly in design, detector type, data processing and construction of hybrid systems. 
This section will give an overview of this evolution and future opportunities for PET. Table 
1 summarises the latest relative spatial resolution of human and animal cameras (Bockisch, 
A. et al., 2009; Cai, W.B. &Chen, X.Y., 2008; Cañadas, M.E. et al., 2008; Kitajima, K. et al., 
2011; Lewellen, T.K., 2008; Wang, C. et al., 2010). The reader is encouraged to consider a 
number of excellent reviews for more detailed discussion.  
 
 
Fig. 1. Detection of coincident gamma rays from positronium annihilation 
 
Human Animal
 
Resolution 
(mm)
 Resolution 
Sensitivity 
(moles detected) 
TOF-PETa 2 – 3 PET 1 – 2 mm 10-15 
SPECTa 6 – 10 SPECT 1 – 2 mm 10-14 
MRIa < 1 MRI 50 µm 10-9 to 10-6 
CTa < 1 CT 50 µm 10-6 
a Time of Flight Positron Emission Tomography; Single Photo Emission Computed Tomography; 
Magnetic Resonance Imaging; Computed Tomography 
Table 1. Comparison of specification of Human and Animal Cameras (Baker, M., 2010; 
Pimlott, S.L. &Sutherland, A., 2011; Smith, S.V., 2005)  
2.1 Human PET cameras 
The first PET camera was developed in the 1950s and by the 90s they were well established 
imaging tools. Its detectors (up to 32 thousand) are arranged in a ring around the subject of 
interest. To obtain an image, the subject containing the PET agent is moved within the field 
of view of the detectors. The radioactivity present in the region of interest is measured and 
the data is processed to generate a 3 D image. The radial distribution of the detectors can be 
varied. For human whole body and brain  imaging PET diameters are approximately 70–87 
cm and 40-50 cm, respectively  (Lee , J.S., 2010; Moses, W.W. et al., 1997). The further the 
detectors are placed apart the more likely the gamma signal will deviate from 180oC (i.e. 
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become non-collinear) compromising spatial resolution. As a result, whole body and brain 
PET have optimum resolutions of approximately 4-6 mm and 2 mm (Lancelot, S. & Zimmer, 
L., 2010). For animal PET, the radial distance of the detector is smaller therefore the achievable 
spatial resolution is 1-2 mm (using 18F). Because the detectors are closer, images can be 
significantly affected (i.e. become blurred) by high energy positrons and gammas (350 – 700 
keV). This comparatively poor spatial resolution of PET created the need to combine it with 
high resolution anatomical data obtained with CT and MRI. Initially this was achieved by 
fusion imaging, where images are taken from independent CT and PET cameras and 
merged to produce a single image. 
By 1998 CT and PET detectors were integrated into a single system (Winant, C.D. et al., 2010). 
The separate images were  superimposed  and produced images of superior quality than their 
respective stand-alone systems. Today, stand alone PET systems comprise less than 10% of the 
PET market and their sales are projected to cease by 2015 (Frost & Sullivan, 2010). There are 
almost 5000 PET-CT systems worldwide, while stand-alone PET tend to be purchased only 
when patient throughput is low or a diagnostic CT camera is in routine operation.  
PET-CT is mostly used for oncology studies (95%), however both neurology (3%) and 
cardiology (2%) are expected to grow to 15 and 10%, respectively. Rubidium-82 is becoming 
the agent of choice  for myocardial perfusion imaging (MPI). Generator produced 82Rb can 
be made widely available. Compared to traditional SPECT agents, such as 99mTc(terefosmin) 
and 201Tl, it provides equivalent or better performance with 5-20 times lower radiation dose. 
The next generation of PET-CT scanners will have 64-slice CT scanners (64 slice) and are 
expected to improve their competitive edge (Winant, C.D. et al., 2010). In neurology, 18FDG 
has already proven its ability in differential diagnosis of dementias, such as Alzheimer’s 
disease from frontotemporal dementia and normal patients. The recent launch of the clinical 
trial of the 18F-PET amyloid imaging agent (18F-AV-45) is expected to further expand the role 
of PET-CT in neurology. 
Even though the PET and CT  images must still be acquired sequentially, the PET-CT 
systems have increased the patient throughput by 30%, reducing time and cost to patient 
and healthcare providers. These systems have enhanced collaboration between the nuclear 
medicine and radiology communities, leading to improved quality of care to the patient and 
increased potential for reimbursements for the radiopharmaceuticals used.  
More recently PET has been able to capitalise on Time of Flight (TOF) techniques to enhance 
image resolution. The first TOF-PET system was developed as far back as the 80s, but only 
in recent times have detectors and data processing capabilities been sufficiently cost–
effective to incorporate this capability into commercial systems (Lee, J.S., 2010). TOF-PET 
can be used to reduce scan time or quantity of radiotracer required to obtain the image 
(Moses, W.W., 2007). This advancement has been particularly important for larger patients 
(>115 kg and BMI > 38) (Lee , J.S., 2010) where small  lesion detection can be difficult. Further 
advances in the timing resolution to less than 500 picoseconds is expected to improve signal to 
noise ratio and image contrast. This will provide more accurate tracer quantification in small 
structures. One drawback for PET-CT is the radiation dose and poor soft tissue contrast. It has 
created the impetus for the  development of MRI and PET hybrid systems (Wolf, W., 2011). 
PET-MRI is emerging as a disruptive technology. (Lancelot, S. & Zimmer, L., 2010). Still only 
used in research communities, the advancement of PET-MRI has relied on improved 
resolution and stability of solid state detectors for PET. These are smaller, cheaper and 
insensitive to magnetic field. Ultimately PET-MRI is expected to significantly reduce the 
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radiation dose to patient, provide higher spatial resolution and superior soft tissue contrast. 
Such characteristics are invaluable for imaging systemic soft tissue disease and the brain. 
Areas such as Alzheimer’s and Parkinson’s disease and neuropsychiatric disorders such as 
schizophrenia and depression in particular, are expected to benefit from such developments. 
2.2 Animal PET cameras 
Dedicated animal PET (microPET) and PET-CT cameras have been available for some time. 
While they have proven to be useful for in vivo measurements of various physiological 
processes in small animals, there are a number of remaining challenges. Of these, spatial 
resolution, sensitivity and radiation dose are the most obvious. Currently high resolution 
microPET cameras have a maximum resolution of ~1 mm (with 18F) and a maximum 
sensitivity of almost 10% (Lancelot, S. & Zimmer, L., 2010). For animal cameras, positron 
energy and specific activity (i.e. radiolabelled product vs unradiolabelled product) of the 
radiopharmaceutical can have a detrimental effect on imaging resolution and sensitivity. In 
addition, CT scanners expose the animal to unnecessary additional high radiation dose. In 
contrast the PET-MRI systems are predicted to reduce this radiation exposure by up to 50%. 
Unfortunately they are still under development and there are no commercial systems 
available at this time. 
3. Cyclotrons – How PET radioisotopes are produced 
PET radioisotopes are proton-rich and are predominantly produced using a cyclotron or 
linear accelerator (International Atomic Energy Agency, 2006; Schmor, P.W., 2010). The 
cyclotron was first conceived by Lawrence at Berkeley, USA in the early 1930s, and by the 
end of that decade it was producing radioisotopes for medical research. Over 15 years later 
there were cyclotrons in St Louis and Boston, USA and London, UK. The first company to 
produce cyclotrons, Scanditronix, was established in 1961, and today there are over 12 
companies producing commercial cyclotrons. The design of a cyclotron can be quite varied 
and tailored to meet the specifications of the users.  
Cyclotrons accelerate a beam of particles such as protons (p), deuterons (d), 3He2+ or 4He2+ 
() in a circular path, with protons being the most common particle used for radioisotope 
production. The particles need to reach certain energies (MeV) for nuclear reactions to take 
place. The particle beam must also have sufficient current (A.hr to mA.hr) to produce 
radioisotopes at reasonable quantities of radioactivity (e.g. 10s GBq to 10s TBq) 
(International Atomic Energy Agency, 2009). 
Today over 350 cyclotrons operate worldwide and most are devoted to radioisotope 
production (International Atomic Energy Agency, 2006; Petrusenko, Y.T. et al., 2009). More 
than half of these cyclotrons produce p with energies from 10 to 20 MeV (majority of these 
(75%) are designed to produce 18F), and others produce energies of up to 70 MeV. The 
number of cyclotrons is expected to increase in conjunction with the expanding role of PET 
and SPECT in molecular imaging. 
The production of radioisotopes involves bombarding a target material with p, d, 3He2+ or  
to cause a nuclear reaction to occur. Typically, these reactions involve a p entering the target 
nuclei and one or more neutrons (n) or alphas () exiting with various gamma emissions. 
These nuclear reactions may be expressed in the following manner, (p, 2n), (p, x) and (p, xn). 
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Reactions with d, 3He2+ or  less utilised, because the achievable energies and currents of 
their respective beams are comparatively lower than for protons.  
3.1 Cyclotron types 
Commercially available cyclotrons can be characterised into three types based on the energy 
of the particles they produce: (Schmor, P.W., 2010) 
3.1.1 Energies up to 20 MeV 
Often termed “baby” cyclotrons, they are the dominant producers of short lived PET isotopes 
(i.e. 11C, 18F, 13N, and 15O). They are generally located in hospital centres, a short distance from 
the PET camera. They produce beams of low currents (< 50 A) and can handle a number of 
target types (typically gas or liquid and, more recently, solid targets). These cyclotrons can 
produce sufficient PET radiopharmaceuticals to support a number of PET cameras. The solid 
targets generally used to produce metal PET isotopes can be positioned external or internal 
(under vacuum) to the cyclotron, requiring extensive cooling systems. 
3.1.2 Energies 20-30 MeV  
These cyclotrons are used to produce both SPECT (e.g. 67Ga, 201Tl, 111In and 123I) and PET 
radioisotopes. Gas, liquid and solid target systems are available. Beam currents are less than 
50 A for gas and liquid, and up to 250 A for solid target systems. These cyclotrons are 
generally dedicated facilities, requiring highly skilled staff to maintain them. These 
production facilities can be located a substantial distance (i.e. different continents) from the 
nuclear medicine department. 
3.1.3 Energy 30-70 MeV 
High intensity and high energy cyclotrons are generally deployed for the production of 
large quantities of radioisotopes for sale. Those operating in the higher energy range are 
commonly used for research purposes. The recently commissioned 70 MeV cyclotron at 
ARRONAX in France (Haddad, F. et al., 2008) will be used to produce radioisotopes for 
imaging and radiotherapy. They include, 67Cu, 211At, 47Sc 52Fe, 55Co, 76Br and 82Sr. These 
radioisotopes can not be produced economically in lower energy systems. The selective 
production of a radioisotope, limiting the production of long lived contaminating 
radioisotopes, can be achieved with this system. For example, 52Fe can be produced via 
55Mn(p,4n)52Fe, and the long lived 55Fe (T1/2 = 2.74 years) is co-produced, however using a 
different reaction, such as 50Cr (,2n)52Fe the production of 55Fe is eliminated. The range of 
beam particles and their respective currents for this cyclotron are summarised in Table 2. 
 
Beam 
Accelerated 
particles
Energy range 
(MeV)
Intensity 
(µA)
p 
H-
HH+ 
30 – 70
17.5
< 350 (x2) 
< 50
d D- 15 – 35 50a 
 He++ 70 <35
a Local radioprotection authorities  in France set the intensity limit for deuterons. 
Table 2. Characteristics of the beams for 70 MeV Cyclotron ARRONAX, France 
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4. Factors governing selection of a radioisotope 
Historically, the criteria governing the selection of a PET radioisotope has been relatively 
simple and largely dominated by the availability, production yield and ability to image. 
Significant advances in design and stability of cyclotrons, cameras and data processing, has 
increased the potential range of PET radioisotopes. Today, the choice of PET radioisotopes is 
influenced by many factors (see Figure 2). It is important to understand how they impact on 
the production and clinical setting as well as on patients when administered repeatedly.  
 
Biological 
pathway
Radioisotope 
chemistry
Nuclear 
Reaction
Cyclotron 
energy & 
particle
Dose
gammas & 
betas
Image Quality
positron & 
gamma 
energy
Half Life
Choice of 
PET
Radioisotope
 
Fig. 2. Criteria governing selection of a PET radioisotope. 
4.1 Half life 
The half life of the PET radioisotope needs to match the biological half life of the carrier 
agent. For applications in diagnosis, this may simply be a radioisotope with a half life long 
enough to see the radiopharmaceutical accumulate in the diseased tissue and clear from 
blood. When imaging to determine prognosis of a patient (ability to respond to treatment) or 
assessing risk (therapeutic index) of an agent, the half life may need to be longer. For the 
latter, understanding uptake and clearance from all critical organs for a patient is important 
when determining its therapeutic index and or appropriate dose. 
4.2 Image quality 
The decay characteristics of the radioisotopes need to match the performance of the imaging 
camera. The resolution of PET remains dependent on three fundamental factors:  
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1. Non-collinearity of annihilating gammas (i.e. deviation from 180o angle on emission of 
511 keV signal) 
2. Positron energy  spectrum 
3. Gamma emissions 
4.2.1 Positrons 
Non-collinearity can be reduced by bringing the detectors closer together. The higher the 
positron energies, the further they  need to travel to lose enough  energy  to form a 
positronium, and this can cause images to blur (Pimlott, S.L. & Sutherland, A., 2011). For 
human PET and particularly TOF-PET systems, the tolerance for the range of positron 
energies is higher than that of an animal PET camera. The spatial resolution of animal PET 
cameras is dependent on the maximum positron energy and its spectrum. Therefore in 
designing animal PET studies one needs to take into consideration the positron energy of 
the PET isotope. 
4.2.2 Gamma emissions 
Gamma emissions from the PET radioisotopes, of specified energies (and intensities), can 
interfere with the image quality, particularly those emitted within the PET discriminator 
window (ie. 350 and 700 keV). This leads to gamma coincidences that result in images of 
poor quality and flat unstructured background. 
4.3 Dose 
PET radioisotopes may decay via a number of pathways and give off x-rays, betas (i.e. 
electrons or positrons) and gammas. All of these emissions contribute to the total absorbed 
dose to the subject. From a production and imaging point of view it is the high intensity 
gamma emissions that cause concern for operators (i.e. production and animal handling 
staff) and applications in the clinical setting. Most PET facilities have been designed to 
handle 18F and do not have sufficient shielding for high energy gammas  Where the patient 
is concerned, the presence of high energy  gammas prevents re-injection (such as that used 
in cardiology) due to accumulated radiation dose.  
4.4 Cyclotron energy 
Cyclotrons need to produce a beam of suitable particles at a desired energy and current for 
the preferred nuclear reaction. Inappropriate beam characteristics will prevent operators 
from producing sufficient quantities for clinic applications.  
4.5 Nuclear reaction 
Most PET radioisotopes are produced by bombarding a target material, which often is 
isotopically enriched. An enriched target is expensive (up to $1000s per target irradiation). 
As only a negligible (0.01%) portion of the target material is converted to the desired 
radioisotope, the target should be treated as an asset and recycled. Sometimes long lived 
gamma emitting radioisotopes can not be chemically removed. Their presence in the used 
target material can prevent its recycling in a timely manner. In such circumstances, a 
sizeable inventory of enriched target material needs to be purchased (e.g. >$250,000 US) to 
permit decay of contaminants prior to reuse.  
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4.6 Chemistry of the PET radioisotope 
The ease, efficiency and cost of production of a PET radiopharmaceutical are affected by the 
chemistry of the radioisotope. The first aspect is the chemical separation of the PET 
radioisotope from the target material; this is more easily achieved if the target element is 
chemically different from the radioisotope. The separation process is generally conducted at 
the cyclotron site.  
The second aspect of PET radiopharmaceutical production is the incorporation of the PET 
radioisotope into the carrier agent. Such processes must be performed relatively quickly and 
preferably quantitatively in order to produce high specific activity products. The production 
of the radiopharmaceutical may require hot-cells and/or an automated system. This can add 
considerable cost to the process and prevent production of the desired PET 
radiopharmaceutical at the site of use.  
4.7 Biological pathway 
Each radioisotope needs to be stably secured to a carrier. However, if the radiolabelled 
carrier breaks down in vivo it is likely to release the radioisotope. As radioisotopes mimic 
their naturally occurring metal ions, they can be expected to excrete from the body using 
normal biological pathways. Hence in choosing the radioisotope, one needs to consider 
these pathways and their potential contribution to the radiation dose to patient. For 
example, copper excretes via the liver and can be recirculated with ceruloplasmin. All the 
copper isotopes,  60Cu, 61Cu, 62Cu and 64Cu are expected to behave in a similar manner. In 
contrast, 86Y, like other lanthanides, will accumulate in bone while the biological pathway of 
89Zr is not known and therefore its behaviour is difficult to predict.  
5. Metal PET radioisotopes 
As mentioned previously the greatest potential for the PET radioisotopes is to provide 
diagnostic information on pathological processes and any changes to them, prior to 
anatomical changes. They have a significant role to play in both the screening of new 
diagnostic and therapeutic target agents in animal studies and in clinical trials. By 
radiolabelling the target agent, such as antibodies, the PET radiopharmaceuticals are used to 
determine the therapeutic index (distribution) of the antibody, the appropriate dose for the 
patient and also assist in selecting patients likely to respond to treatment.   
Radiometal isotopes  can also be incorporated into a ligand or complexing agent and used to 
monitor various biological properties such as blood flow, hypoxia or glomerular filtration 
and or organ function (e.g. heart, kidney or liver) (Smith, S.V., 2004 and references within). 
In this case, the design of the ligand and the resultant metal complex dictates the function of 
the PET radiopharmaceutical.  
If the ligand is bi-functional, one portion of the molecule will be responsible for complexing 
the metal radioisotope and the other will contain a reactive group (e.g. amino, carboxylic 
acid or isothiocyanate) that is responsible for coupling the metal complex to a target agent. 
For target agents with long biological half lives (i.e. hours and days) it is important to ensure 
the radiolabel is secured and stable in vivo until the target agent clears from the body. This 
ensures the PET signal in vivo is from the radiolabelled target agent and not the radioisotope 
in its ionic state or non-specifically bound to naturally occurring biological components. 
Furthermore, the half life of the radioisotope needs to be sufficiently long enough to monitor 
the localisation of its carrier to the disease site and attain a signal to noise ratio of at least 2 
fold. Table 3 summarises metal PET radioisotopes reported for these applications. 
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Isotope Half Life 
Maximum + 
Energy (keV) 
Mean + 
Energy (keV)
+ Intensity 
(%) 
 energy 
(keV) (Intensity %) 
48V 16.0 d 695 290 49.9 944 (7.9); 984 (100); 1312 (98.2) 
52Fe 8.3 h 804 340 55.0 169 (99.2) ; 338 (1.6) 
52mMn 21.1 m 2633 1174 94.8 1434 (98.3) 
52Mn 5.6 d 576 242 29.6 
744 (90.0) ; 848 (3.3); 936 (94.5) ; 
1434 (100.0) 
55Co 17.5 h 
1021 
1113 
1499 
436 
476 
649 
25.6 
4.3 
46.0 
477 (20.2); 931 (75.0); 1317 (7.1); 
1409 (16.9) 
60Cu 23.7 m 
1835 
1911 
1981 
2946 
3772 
805 
840 
872 
1325 
1720 
4.6 
11.6 
49.0 
15.0 
5.0 
467 (3.5); 826 (21.7); 1035 (3.7); 
1333 (88.0); 1792 (45.4); 1862 (4.8); 
3124 (4.8) 
61Cu 3.3 h 
559 
932 
1148 
1215 
238 
399 
494 
524 
2.6 
5.5 
2.3 
51.0 
283 (12.2) ; 656 (10.8) ; 1185 (3.7) 
62Zn 9.3 h 605 259 8.4 508 (14.8) ; 548 (15.3); 597 (26.0) 
62Cu 9.7 m 2926 1316 97.2  
63Zn 38.5 m 
1382 
1675 
2345 
600 
733 
1042 
4.9 
7.0 
80.3 
670 (8.2) ; 962 (6.5) 
64Cu 12.7 h 653 278 17.6  
66Ga 9.5 h 
924 
4153 
397 
1904 
3.7 
51.0 
834 (5.9) ; 1039 (37.0) ; 2190 (5.3); 
2752 (22.7) ; 4295 (3.8) 
68Ga 1.1 h 
822 
1899 
353 
836 
1.2 
87.9 
1077 (3.2) 
81Rb 4.6 h 
580 
1026 
254 
448 
1.8 
25.0 
190 (64.0) ; 446 (23.3) ; 510 (5.3) 
82Rb 1.3 m 
2601 
3378 
1168 
1535 
13.1 
81.8 
777 (15.1) 
83Sr 1.4 d 
830 
1212 
363 
531 
3.1 
9.0 
382 (14.0) ; 418 (4.4); 763 (30.0) 
86Y 14.7h 
1221 
1545 
1988 
3141 
535 
681 
883 
1437 
11.9 
5.6 
3.6 
2.0 
515 (4.9) ; 581 (4.8); 628 (32.6) ; 
646 (9.2); 703 (15.4); 777 (22.4) ; 
836 (4.4) ; 1077 (82.5) ; 1153 (30.5); 
1443 (16.9); 1854 (17.2); 1921 
(20.8) 
89Zr 78.4 h 902 396 22.7 909 (99.0) 
94mTc 52.0 m 2439 1094 67.6 871 (94.2) ; 1522 (4.7) ; 1869 (5.7) 
94Tc 4.9 h 811 358 10.5 
703 (99.6) ; 850 (95.7) ; 871 (99.9) ; 
916 (7.6) 
110In 1.2 h 2260 1043 62.0 658 (98.0) 
Table 3. Selection of Metal PET radioisotopes and their physical characteristics 
(http://www.nndc.bnl.gov/; International Atomic Energy Agency, 2009) 
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Their physical characteristics including mean positron energy, gamma emissions and half 
lives are given. Only gamma emissions of greater than 5% intensity, or that are within the 
PET detector window, or contribute significantly to operator dose have been included. All of 
the radioisotopes listed emit positrons of sufficient energy and intensity  
(>  10%) for imaging with available PET cameras. Further each radioisotope listed can be 
produced in commercially available cyclotrons. 
5.1 Half life 
The half lives of the radioisotopes presented in Table 3 vary from minutes to days. They 
may be classified into groups based on these half lives (see Figure 3). The timeframes chosen 
take into consideration the time to purify the radioisotopes, its incorporation into a carrier 
agent and the packaging and transport  of the resultant radiopharmaceutical across 
continents.  
The first class of radioisotope (t1/2 = 1- 60 mins) is generally used as surrogates for cations in 
vivo or incorporated into complexing agents. A number of the radioisotopes can be 
produced from a generator system (see Figure 4) making them more accessible to the wider 
PET community. Radioisotopes with longer half lives (hours to days) are best suited for 
studying the pharmacokinetics or dynamics of large molecules such as peptides, proteins 
and particles.  
There are 6 PET radioisotopes (82Rb, 62Cu, 52mMn, 60Cu, 63Zn and 94mTc), with half lives 
varying from 1.3 – 52 min. Three, 82Rb, 62Cu and 52mMn are particularly attractive because 
they can be produced from a generator utilising the decay of 82Sr, 62Zn or 52Fe to produce the 
respective daughter PET radioisotopes (see Figure 4). The 82Sr/82Rb and 62Zn/62Cu 
generators have been commercially available for some time. The radioisotopes 60Cu, 63Zn 
and 94mTc must be produced and used at or within a short distance from the cyclotron 
production centres. 
 
 
Fig. 3. Classification of positron emitting radioisotopes. 
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Fig. 4. Decay scheme for generator produced 52m Mn, 82Rb and 62Cu 
For example, 82Rb+ (t1/2= 1.3 min) is used in myocardial perfusion studies; it acts as a 
surrogate for K+. The very short half life of 82Rb makes whole body imaging a challenge and 
precludes imaging after 10 mins. As a result activities of up to 1.5 GBq are administered to 
patients. Heart, kidney, lungs and pancreas receive an absorbed radiation dose of 5.1, 5.0, 
2.8 and 2.4 mGy per MBq, respectively. This is significantly less than both 201Tl and 99mTc 
sestamibi SPECT agents (Senthamizhchelvan, S. et al., 2011). The long half life of the parent 
82Sr (t1/2= 25.55 days) permits its transport throughout the world. 
The radioisotopes 60Cu (t1/2= 23.7 min) and 62Cu (t1/2= 9.6 min) have identical chemistry and 
can be interchanged depending on the carrier agent and the biological processes under 
investigation. The 62Cu is produced from the parent 62Zn (T1/2 = 9.3 hour); its short half life 
requires the generator to be prepared daily. 
The story with 52mMn is more complex. It is produced from the positron-emitting parent 52Fe 
(t1/2=8.3 hours) and then decays by positron emission to the long-lived daughter 52Mn 
radioisotope (t1/2=5.591 days). While the 52Mn emits a low energy positron its 
extraordinarily high energy gamma detracts from its use in PET imaging. A recent study, 
investigating the effect of the daughter 52mMn on the 52Fe PET image quality showed there 
was minor degradation, compared to 18F.  
The positron energies for 60Cu and 63Zn are of similar intensity, the latter having 
comparatively less gamma emissions. It is surprising 63Zn has not been reported in the 
literature more often. As Cu(II) and Zn(II) complex with similar chelating agents, there is 
potential to substitute 63Zn for 60Cu in emerging  blood flow or hypoxia markers.  
Technetium-94m also has a short half life with a relatively high intensity positron emission. 
It decays to the positron emitter 94Tc, which further decays giving off a large proportion of 
high energy gammas. The 94mTc could potentially act as a surrogate for the SPECT 99mTc 
agents but negligible improvement in imaging resolution is unlikely to  compensate for the 
increased dose both to operator and subject.  
The application of radioisotopes ranging in half life from 1 hour to less than a day is varied. 
They are readily incorporated into chelators or carrier agents but their stability will be 
dependent on their respective coordination chemistry and redox chemistry. Generator 
produced 68Ga (t1/2=1.1 hours) has been used to radiolabel a range of peptides including 
derivatives of octreotide (Gabriel, M. et al., 2007; Henze, M. et al., 2001) and arginine-
glycine-aspartate (RGD) (Li, Z.B. et al., 2008; Liu, Z.F. et al., 2009). However, the short half 
life of 68Ga can create challenges for the synthesis of the radiopharmaceutical and its 
imaging. The high energy positrons given off by 110In and 66Ga would prohibit their use as 
surrogates for 111In and 67Ga SPECT agents, while their high intensity gammas (1 to 4 MeV) 
require considerably more lead  shielding for handling than classical PET agents. 
52
Fe 
52m
Mn 
52
Mn 
82
Sr 
82
Rb 
82
Kr 
62
Zn 
62
Cu 
62
Ni 
t 1/2 = 8.28 h t 1/2 = 25.5 d t 1/2 = 9.19 hr 
t 1/2 = 21.1 m t 1/2 = 1.27 m t 1/2 = 9.74 m 
52
Cr 
t 1/2 = 21.1 m 
t 1/2 = 5.6 d 
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All PET isotopes with half lives greater than 12 hours have greater flexibility in PET 
imaging. Of the radioisotopes selected 64Cu, 89Zr and 48V have the most favourable positron 
energies for imaging but only 64Cu does not have significant gammas to compromise its 
application.  
5.2 Gamma emissions - Safety 
As mentioned previously, some gamma emissions from the PET isotopes can affect PET 
image quality, choice of shielding in production facilities and cause unnecessary absorbed 
dose to the subject. Shielding suitable for 18F may not be sufficient to shield gammas with 
energies significantly greater than 500 keV (Madsen, M.T. et al., 2006). Figure 5 illustrates a 
simple comparison of the relative energy and the intensities of gammas emitted from some 
of the radioisotopes given in  Table 3. The data clearly show that gammas generated from 
the decay of 60Cu, 86Y and 89Zr are of significantly higher energies than that of 18F; therefore 
these radioisotopes will require substantially more lead shielding for processing compared 
to  that used for 18F  productions. Gammas in the range of 350 – 700 keV (shaded green on 
image) from  decay of  62Zn and 86Y will interfere with PET image quality, resulting in a 
reduced signal to noise ratio. In stark contrast, 62Cu and 64Cu have no significant gammas 
that will interfere with camera quality, nor do they  require significant changes to current 
lead shielding used in PET facilities. 
 
 
Fig. 5. Compares relative gamma emissions (blue) and their intensities (yellow) for selected  
radioisotopes from Table 3.  
6. Radiation dose 
As the energy and the probability of gamma emissions is specific for each radioisotope, they 
can be used to calculate the energy released per decay in the form of photons. The energy 
released per decay may be represented as MeV (Bq s)-1, where 1 Bq = 1 decay per second.  
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Radiation dose received by an operator or patient is measured in Sievert, Sv. One Sv is 
equivalent to the energy absorbed per kilogram of mass (J/kg). In the case of the operator 
who is positioned at some distance from the radiation source, the dose received in Sv is a 
function of the intensity of the radiation, type of radiation, distance from the source and the 
time exposed to the source. It is convenient to discuss the dose rate in Sv/hr, so that the 
operator can determine the dose received for a specific time period.  
Figure 6 illustrates the dose rate per unit of radioactivity received by an operator at one 
metre distance from each unshielded PET radioisotope source. It shows the effect of high 
energy gammas can vary by 10-fold across the series of radioisotopes listed in Table 3. These 
doses also need to be considered when dispensing the radiopharmaceutical and when 
injecting the subject (i.e. patient or animal) as they effectively become a radioactive source 
and shielding under these circumstances is not always practical.  
 
 
Fig. 6. The dose rate per unit of radioactivity received by an operator at one metre from an 
unshielded source.  
6.1 Shielding 
The dose rate values in Figure 6 can be used to determine the shielding for the production, 
handling and storage of the PET isotopes. The shielding can then be adjusted to ensure the 
radiation exposure to the operator is kept within an acceptable level. The following 
relationship can be used to determine the shielding required: 
 I = I0 e -
t  (1) 
where: 
I = intensity of the radiation after shielding,  
I0 = intensity before shielding,  
t = thickness [cm] of shielding material (in this case lead), and  
 = linear attenuation coefficient [cm-1]. 
The linear attenuation coefficient takes into account the effect of photoelectric absorption, 
Compton collision, pair production and Rayleigh scattering. The relationship between linear 
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attenuation and the energy coefficients for a range of photon energies is illustrated in Figure 
7 (Hubbell, J.H., 1969). The curve shows that for higher energy gammas travelling through 
lead, the attenuation is lower per unit of distance travelled. As a result, for the same 
intensity of radiation, a greater thickness of lead is required to shield an operator from 
higher energy photons than for lower energy photons. 
Photoelectric effect, Compton scattering and pair production can result in secondary 
photons. These photons have a finite probability of contributing to the total dose received by 
the operator. The extent to which these secondary photons contribute is described through 
the use of a build-up factor. For simplification this will be ignored here, but it should be 
noted that it is a multiplicative factor, that is, always greater than one. Further the 
multiplication factor is dependent on the energy of the incident photons, the atomic number 
of the shielding material and the thickness of the shielding. For further information 
regarding shielding calculations refer to Principles of Radiation Shielding (Chilton, A.B. et 
al., 1984). To calculate the thickness of lead required to shield an operator for a quantity of 
radioactivity, the radiation is assumed to be at the highest energy gamma associated with 
the radioisotope decay. Further if we set the maximum permitted operator dose at 12 mSv 
per working year, the maximum dose rate for operator exposure is ~0.00625 mSv/hr where 
one year is equivalent to 48 wks at 40 hours/wk. 
 
 
Fig. 7. Log-Log plot of linear attenuation coefficients for lead as a function of energy. 
To obtain the thickness of lead required to reduce the original intensity I0 to the desired 
value I, equation (1) is rearranged to: 
 t = -()-1 ln(I/ I) [cm] (2) 
Assuming the source has 1Ci (37 GBq) of a PET radioisotope, the thickness of lead required 
to reduce the operator dose rate to 0.00625 mSv/hr may be calculated using (2). It is useful 
to combine the data of Figure 6 with Figure 7 and compare the dose rate per activity plotted 
with the relative thickness of required lead shielding to reduce the dose to specified levels in 
Figure 8. In other words, the data show the relative thickness of shielding for the same 
amount of radioactivity for each PET isotope. For 60Cu, a 5 fold greater thickness of lead 
shielding is required compared to  an equivalent amount of 64Cu radioactivity.  
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It is important however to note that the relative order of shielding required for each PET 
radioisotope in Figure 8 does not always correspond directly to the total dose rate discussed 
above. For example, shielding for 86Y, 66Ga, 55Co, 94mTc, 63Zn, 68Ga, 89Zr, 61Cu, 83Sr, 62Zn, 81Rb 
and 64Cu is significantly higher than one might have anticipated when examining only dose. 
In contrast, the shielding required for 52Mn, 48V, 94Tc, 110In, 52Fe 82Rb, 18F , 62Cu and 68Ga, are 
all lower. This emphasises the importance of considering dose and shielding together, even 
when the high energy gammas are of low intensity, when handling and administering the 
PET radiopharmaceuticals. These results concur with recently reported findings (Holland, 
J.P. et al., 2011) where the occupational exposure of staff increased when handling low 
amounts of activity (~1-25 mCi) of 86Y and 89Zr compared to significantly  higher quantities 
of 18F activity (~400-500 mCi).  
Furthermore, transport of these types of PET isotopes requires modification of shipment 
containers or significant reduction in the amount of activities to be shipped. The emission of 
high energy gammas from 86Y and 89Zr allow only ~1/162 and ~1/44 respectively of the 
maximum activity of 18F to be transported in approved PET radioisotope shipment 
containers in the USA (Holland, J.P. et al., 2011). Negligible change in shielding would be 
required for 64Cu.  
 
 
Fig. 8. Dose rate per unit activity and the required lead shielding for each PET radioisotope.  
7. Positron energy - Image quality 
It is important to consider the energies of the positrons emitted from the PET radioisotopes 
when determining their application. Because the positron has to lose energy before it 
annihilates, it travels and interacts with tissue over a significant range (i.e. millimetres). As 
the density of the tissue can affect the rate at which the energy is lost from the positron, one 
may also expect the positron to travel further in lung tissue (because it is predominantly air). 
PET images in this region will be “blurred” and the spatial resolution will be poorer 
compared to other parts of the body where the density of tissue is higher. In contrast, for 
bone, which is considered electron rich and of dense composition, the PET image appears 
comparatively sharper. 
www.intechopen.com
 
Radioisotopes – Applications in Bio-Medical Science 
 
214 
For small animal PET cameras, PET radioisotopes emitting high energy positrons have a 
detrimental effect on image quality (Laforest, R. & Liu, X., 2008; Partridge, M. et al., 2006). 
Laforest and Lui 2008, reported that both the range the positron travels and the presence of 
cascades of gamma rays contributed to poor signal to noise ratios. In the same work, they 
compare phantoms containing either 60Cu, 61Cu, 64Cu, 94mTc or 86Y and demonstrate how the 
positron energy can affect the image resolution. 
Improvement in spatial resolution of animal PET cameras using these radioisotopes can be 
achieved by an increase in imaging time and a reduction in the coincidence window limits 
to prevent contamination from other decay modes (Vandenberghe, S., 2006). To do this the 
subject either needs to be injected with more radioactivity or kept in the field of view of the 
camera for longer periods of time. A more sophisticated approach to improve image quality 
is to develop image reconstruction algorithms that consider the nuclear decay and 
tomography response (Laforest, R. & Liu, X., 2008; Ruangma, A. et al., 2006).  
Though the development of cyclotrons continues to flourish and in parallel the range of PET 
isotopes, understanding the track structure of positrons emitted is largely unresolved. 
Attempts to use Monte Carlo modelling to illustrate the tracking of positrons in tissues have 
been made by a number of groups. Work by Sanchez-Crespo et al. (Sanchez-Crespo, A. et 
al., 2004) has shown how the density of tissue can change the resolution of an image. But 
such modelling is unlikely to comprehensively predict the positron behaviour or its 
microdosimetry, until accurate measurements of the cross sections for the interaction of 
positrons and electrons with various biological molecules have been attained. Such data 
have the potential to improve the analysis of PET data and therefore the quality of PET 
images, as well as improve accuracy of absorbed radiation dose calculations. 
A closer examination of the PET radioisotopes considered in this chapter (see Table 3) shows 
that many of the isotopes can emit a number of positrons through the allowed decay paths. 
Understanding the kinetic energy spectra for each of these positrons is useful, as  they affect 
the quality of the image to different degrees. In using equation 3  the positron energy spectra 
are calculated for the highest intensity positron per radioisotope in a similar manner to that 
reported by Le Loirec (Le Loirec, C. & Champion, C., 2007a).  
 N(E) = C F(Z,E) p E (Emax – E)2 (3) 
F(Z,E) = 2  ( 1 – e-2 
 = -Z  E/p 
Where:  
E = total energy of the positron;  
Z = atomic number;  
a = fine structure constant; 
p = momentum of positron;  
Emax = maximum allowed energy of positron;  
C = normalisation constant. 
The spectrum of the dominant positron emission for each radioisotope is illustrated in 
Figure 9. The data demonstrate the range of positron energies per isotope and therefore the 
relative distance they are likely to travel in vivo. Of course, these values do not take into 
account the tissue density, but they can be used to give an indication of the relative quality 
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of images to be obtained for each PET radioisotope. The green shaded area represents  the 
range of positron energy spectrum for 18F for comparison. Clearly positron spectra of 52Mn, 
62Zn, 64Cu and 48V correlate best with 18F and potentially could give similar image quality. 
However the interfering gammas for all of these radioisotopes, except 64Cu, may 
compromise image quality. 
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Fig. 9. The spectrum of the dominant positron emission for each radioisotope 
Figure 10 (a) and (b) illustrate the relative intensity of kinetic energy spectra for + decays (in 
colour dotted curves) of 61Cu and 66Ga respectively. These spectra do not take into account the 
relative intensity of each positron. Conversely the black curve is the result of the accumulated 
spectra taking into consideration the relative intensities of each. Figure 10a shows how a low 
energy positron (559 keV) can become insignificant when a high intensity of the higher energy 
positron (1215 keV) is present. A similar effect is evident for 66Ga however the shape is 
significantly different and suggests the signal to noise ratio would be poorer. 
 
  
a  61Cu     b  66Ga 
Fig. 10. The relative kinetic energy spectra of the positrons emitted by 61Cu and 66Ga (Le 
Loirec, C. & Champion, C., 2007a; 2007b) 
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8. Production of metal positron emitting isotopes 
There are many radioisotopes that can be produced with a cyclotron. The challenge in each 
case is to develop targetry (target material and loading system) that allows it to be kept 
stable in the beam of the accelerated particles and to remove the desired radioisotope 
quickly and efficiently. Unlike the well-known PET isotopes 11C, 18F and 15N which are 
produced using gas or liquid based targetry, the metal radioisotopes listed in Table 3 are 
mostly generated from solid targets of metal based materials (e.g. metal element or metal 
oxide). The target can be placed within the cyclotron (under vacuum) or external to the 
cyclotron. In each case the target system needs to tolerate heat generated from the particle 
reactions. Depending on the energy and current of the beam (A or mA) the cooling systems 
can be quite elaborate. 
As the number of nuclear reactions is potentially large, one needs to design the target so that 
the preferred nuclear reaction dominates. This may be achieved in a number of ways: 
a. choice of beam particle [i.e. p, d, or ] 
b. energy of the beam 
c. target material [i.e. natural or enriched isotope of target element].  
The use of enriched isotopes for these types of reactions can add considerable cost  to the 
production of a radioisotope. It is wise to treat the material as capital and recycle it for re-
use. By using an enriched isotope for the target, one can also prevent or reduce the 
production of contaminating radioisotopes. If these contaminating radioisotopes have high 
gamma emissions or different half lives from the desired radioisotope, they can affect the 
shielding and timing of a production process, as well as delay the recycling of enriched 
target material. For example, 67Ga is a SPECT agent produced by proton bombardment of 
enriched 68Zn. By-products of this reaction are 66Ga (t1/2=9.5 hr) and 65Zn (t1/2=244 days), 
both of which produce high energy gammas. The former is often left to decay before the 
67Ga can be processed. Furthermore shielding of hot cells needs to be increased to reduce the 
dose to operators. The presence of the latter, 65Zn, prevents recycling of the 68Zn target 
material. Therefore, large inventories (~100g costing ~$250,000 US) of enriched 68Zn is 
maintained so irradiated samples can be left to  decay  before recycling. The presence of a 
long lived radioisotope contaminant in the desired PET product can impact on its expiry  
time and use. Good target design is essential to ensure cost effectiveness and high quality 
product. 
8.1 Generator produced PET isotopes 
There is added complexity to the production and separation of short lived radioisotopes. For 
example, 82Rb (T1/2 = 1.3 min), 68Ga (T1/2 = 67.6 min) and 62Cu (T1/2 = 7.6 min) are all 
produced from their respective parent isotopes in a generator. These generators are then 
supplied to the PET facilities and milked periodically to resource the desired isotopes.  
8.2 Nuclear reactions for PET radioisotopes 
The type of nuclear reactions to produce a PET radioisotope can be quite varied. Table 4 
summarises some of the more successful production routes for the PET radioisotopes, their 
nuclear reactions, useable energy range and the maximum cross section from the excitation 
function. The abundance of target element used for each reaction is also listed. 
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Nuclide Nuclear Reaction 
Energy 
Range 
[MeV]
Natural 
Abundance 
[%]
Energy at 
Maximum 
[MeV]
Maximum 
Cross-Section 
[mb] 
44mSc natTi(p, x)44mSc 28 - 48 Natural 34 17 
48V 48Ti(p, n)48V 6 - 50 73.8 12 380 
52Mn natFe(d, x)52Mn 28 - 49 Natural 38 166 
52Fe** 50Cr(, 2n)52Fe 20 - 42 4.4 29 , 25 21 , 60 
52Fe 55Mn(p, 4n)52Fe 40 – 60 100.0 54 100 
52Fe 52Cr(3He, 3n)52Fe 25 – 40 83.8 19 550 
55Co 54Fe(d, n)55Co 5 - 10 5.8 7 84 
55Co 56Fe(p, 2n)55Co 20 – 30 91.7 25 70 
55Co 58Ni(p, )55Co 10 – 24 68.3 17 40 
55Co natNi(p, x)55Co 11 – 22 Natural 17 24 
55Co natFe(p, x)55Co 16 - 42 Natural 25 60 
55Co 55Mn(3He,3n)55Co 15 – 25 100.0 19 550 
61Cu 61Ni(p, n)61Cu 3 – 19 1.1 10 480 
61Cu natNi(, p)61Cu 15 – 25 Natural 27 450 
61Cu 59Co(a, 2n)61Cu 18 - 60 100.0 28 470 
61Cu 61Ni(p, n)61Cu 4 – 19 1.1 10 500 
62Zn natCu(p, x)62Zn 14 - 61 Natural 23 75 
62Zn natZn(p, x)62Zn 28 - 70 Natural 37 45 
63Zn natCu(d, x)63Zn 6 – 40 Natural 17 420 
63Zn natCu(p, x)63Zn 6 – 50 Natural 12 350 
63Zn 63Cu(p, n)63Zn 4 – 40 69.2 12 460 
63Zn 60Ni( n)63Zn 8 – 25 26.1 19 550 
64Cu 61Ni(, p)64Cu 5 – 15 0.9 10 148 
64Cu 64Ni(p, n)64Cu 3 - 40 0.9 11 700 
64Cu 64Ni(d, 2n)64Cu 5 - 50 0.9 15 800 
64Cu 66Zn(d, )64Cu 8 - 14 27.9 11 27 
64Cu natZn(p, x)64Cu 
20 – 30
30 - 65
Natural 
23
40
15 
25 
64Cu 68Zn(p, n)64Cu 16 – 45
45-100
18.8 25
70
75 
60 
66Ga 66Zn(p,n)66Ga 7 - 30 27.8 12.5 650 
66Ga natZn(p x)66Ga 5 - 70 Natural 15 150 
66Ga 63Cu(, n)66Ga 10 - 26 69.2 16 690 
68Ga 68Zn(p,n)68Ga 5 - 35 18.8 11 830 
68Ga 65Cu(,n)68Ga 11- 22 30.83 17 850 
68Ge natZn(, x)68Ge 15 - 100 Natural 30 155 
68Ge 66Zn(, 2n)68Ge 20 - 40 27.8 30 550 
68Ge 69Ga(p, 2n)68Ge 13 – 36 60.1 20 558 
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68Ge natGa(p, x)68Ge 13 - 56 Natural 21 325 
81Rb 81Kr(p, x)81Rb 
15 - 35
35 - 100
Natural 
25
50
100 
190 
82Rb 85Rb(p, 4n)82Sr 38 - 100 72.2 52 150 
82Rb natRb(p, x)82Sr 45 - 60 72.2 52 100 
82Rb 82Kr(, 3n)83Sr 25 - 40 11.6 30 280 
82Sr 82Kr(3He, 3n)82Sr 19 - 35 11.6 35 275 
86Y 86Sr(p, n)86Y 7 – 50 9.9 13 950 
86Y natZr(d, x)86Y 31 - 50 Natural 43 39 
86Y 86Sr(d, 2n)86Y 5 – 30 9.9 19 691 
86Y 88Sr(p, 3n)86Y 30 – 85 82.6 40 470 
86Y 85Rb(, 3n)86Y 29 - 50 72.2 41 800 
89Zr 89Y(p, n)89Zr 5 - 50 100.0 14 780 
89Zr** 89Y(d, 2n)89Zr 5 - 40 100.0 16 , 20 700 , 1100 
94mTc 94Mo(p, n)94mTc 7 - 18 9.3 12 460 
** Two references quoting different values. 
Table 4. Common production routes of PET radioisotopes (Al-Abyad, M. et al., 2009; Aydin, 
A. et al., 2007; Brodzinski, R.L. et al., 1971; Fulmer, C.B. & Williams, I.R., 1970; Hermanne, A. 
et al., 2000; Hille, M. et al., 1972; Ido, T. et al., 2002; International Atomic Energy Agency, 
2009; Khandaker, M.U. et al., 2009; Sadeghi, M. et al., 2010; Sadeghi, M. et al., 2009; 
Szelecsényi, F. et al., 2001; Szelecsenyi, F. et al., 2006; Takacs, S. et al., 2003; Takacs, S. et al., 
2007; Tarkanyi, F. et al., 2005) 
The cross sections for the production of 68Ga via p and  bombardment of 68Zn and 65Cu 
targets respectively, are similar. The former production route would be preferred due to the 
wider availability of p producing cyclotrons. However it is important to note that 66Ga 
which has a longer half life, can be produced via p bombardment of 66Zn in the same energy 
region. As the natural abundances for 64Zn, 66Zn and 68Zn are 48.6%, 27.9 % and 18.8 %, 
respectively, even small amounts of 64Zn and 66Zn present in enriched (>95%) 68Zn will 
contribute to the production of contaminating isotopes. 
Generators for the production of 82Rb (T1/2 = 1.3 min) and 68Ga (T1/2 = 67.6 min) are 
commercially available. The long half lives of their respective parents, 82Sr (T1/2 = 25.3 days) 
and 68Ge (T1/2 = 270.8 days) means the generators have a life-time of months to almost a 
year. However the challenge in the production of these generators is that they must stand 
up to repeated milking over at least twice the lifetime of the generator to demonstrate that 
there is no breakdown of the column material or any leaching of contaminating long lived 
radioisotopes. The parent of 62Cu, 62Zn has a short half-life and needs to be prepared daily. 
This generator can be milked multiple times however the short half-life of the 62Zn limits the 
lifetime of its use to less than a day. 
A comparison of the maximum cross section and the energy range suitable for the 
production of each PET isotope on a 30 MeV cyclotron is illustrated in Figure 11. The green 
and blue icons represent p and d reactions at the maximum cross section. The associated 
error bar reflects the useable energy ranges (cross section >10 mb) for the respective 
reactions.  
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Fig. 11. Radioisotopes produced using protons and deuteron in the energy range  0-30 MeV.  
In general, the production of radioisotopes via proton bombardment are more common 
across the energy ranges, as their high cross sections provide for higher yields. In contrast, 
nuclear reactions with deuterons are less common. This is not surprising as maintaining a 
stable beam of these particles at a high current is more difficult.  
Reactions for 86Y, 68Ga, 64Cu, 89Zr, 66Ga, 68Ge, 61Cu , 63Zn, 94mTc and 48V in Figure 11 have a 
very high probability. However the cost effectiveness of their production relies on the 
enrichment of their target material. The targets used to produce 89Zr, 48V, 63Zn , 68Ga and 
68Ge are of high (>60%) natural abundance (identified by the orange circles in Figure 11) and 
therefore will yield high quantities of these radioisotopes at comparatively reasonable cost. 
Once the preferred reaction route is identified then a separation method for the radioisotope 
needs to be developed. The separation methods need to be robust, reliable and cost effective 
in order to maintain a routine supply of the desired radioisotope.  
9. Conclusions 
Designing a PET radiopharmaceutical relies on careful consideration of a number of factors. 
They include the physical characteristics of the radioisotope, its chemistry and half life. For 
the former the critical aspects are the positron and gamma energies. A radioisotope with a 
low maximum positron energy is always preferred. The presence of any gammas contribute 
to radiation dose. High energy gammas require additional lead shielding and this 
significantly increases the cost of infrastructure. Gammas in the 350-700 keV range decrease 
PET image resolution and will require longer imaging times. The application of the 
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radiopharmaceuticals in PET imaging will depend on the radioisotope’s chemistry and 
biological half-life. The former requires the separation and radiolabelling to take place 
rapidly without extensive infrastructure and technical skills. Advances in the ability of 
cyclotrons to produce p, d and particles have substantially increased the range of metal 
PET radioisotopes that can be produced. However the yield and the cost effectiveness of the 
radioisotope production are ultimately dependent on the choice of nuclear reaction and the 
natural abundance of the target material used. Metal PET radioisotopes are ideal for 
labelling small molecules, peptides, proteins and particles via chelators and clearly have a 
role in the diagnosis of disease and risk assessment of new drugs. Of the 21 metal PET 
radioisotopes evaluated, 61Cu and 64Cu best meet the criteria for human use.  
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